Role of the VEGFR3/VEGFD receptor axis in TGFβ1 activation of primary prostate cell lines
暂无分享,去创建一个
[1] M. Stearns,et al. Dysplasia of human prostate CD133hi sub‐population in NOD‐SCIDS is blocked by c‐myc anti‐sense , 2009, The Prostate.
[2] P. Heikkilä,et al. VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer. , 2007, American journal of clinical pathology.
[3] I. Giannopoulou,et al. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma. , 2007, European Journal of Surgical Oncology.
[4] M. Hung,et al. The role of the VEGF-C/VEGFR-3 axis in cancer progression , 2006, British Journal of Cancer.
[5] J. Shih,et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. , 2006, Cancer cell.
[6] S. Jakowlew. Transforming growth factor-beta in cancer and metastasis. , 2006, Cancer metastasis reviews.
[7] K. Jennbacken,et al. Expression of vascular endothelial growth factor C (VEGF‐C) and VEGF receptor‐3 in human prostate cancer is associated with regional lymph node metastasis , 2005, The Prostate.
[8] N. Kyprianou,et al. Transforming growth factor beta and prostate cancer. , 2005, Cancer treatment and research.
[9] J. Sleeman,et al. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo , 2004, International journal of cancer.
[10] M. Stearns,et al. Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4tΔ773–1081 overexpression is diagnostic for sentinel lymph node metastasis , 2004, Laboratory Investigation.
[11] P. Scardino,et al. Expression of vascular endothelial growth factor receptor‐3 (VEGFR‐3) in human prostate , 2004, The Prostate.
[12] J. M. Mullin. Epithelial Barriers, Compartmentation, and Cancer , 2004, Science's STKE.
[13] J. Sleeman,et al. Expression of vascular endothelial growth factor (VEGF)‐C and VEGF‐D, and their receptor VEGFR‐3, during different stages of cervical carcinogenesis , 2003, The Journal of pathology.
[14] Michael J. Wilson,et al. Expression of matrix metalloproteinase‐2 and ‐9 and their inhibitors, tissue inhibitor of metalloproteinase‐1 and ‐2, in primary cultures of human prostatic stromal and epithelial cells * † , 2002, Journal of cellular physiology.
[15] D. Witte,et al. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. , 2002, Anticancer research.
[16] S. Rafii,et al. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. , 2002, Blood.
[17] Y Sakai,et al. HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis , 2022 .
[18] K. Alitalo,et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis , 1999, British Journal of Cancer.
[19] K. Alitalo,et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[20] J. Taipale,et al. Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion. , 1998, Advances in cancer research.
[21] M. Stearns,et al. IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. , 1997, Invasion & metastasis.
[22] H. Bonkhoff,et al. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model , 1996, The Prostate.
[23] K. Alitalo,et al. A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.
[24] H. Bonkhoff. Role of the basal cells in premalignant changes of the human prostate: a stem cell concept for the development of prostate cancer. , 1996, European urology.
[25] M. Stearns,et al. IL-10 blocks collagen IV invasion by "invasion stimulating factor" activated PC-3 ML cells: upregulation of TIMP-1 expression. , 1995, Oncology research.
[26] K. Alitalo,et al. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. , 1992, Cancer research.
[27] D. S. Coffey,et al. Etiology and disease process of benign prostatic hyperplasia , 1989, The Prostate. Supplement.